SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:oru-61451"
 

Search: onr:"swepub:oai:DiVA.org:oru-61451" > Intradermal HIV-1 D...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Intradermal HIV-1 DNA immunization using needle-free ZetajetTM injection followed by HIV-modified vaccinia virus Ankara vaccination is safe and immunogenic in Mozambican young adults : a phase I randomized controlled trial

Viegas, Edna Omar (author)
Instituto Nacional de Saúde, Maputo, Mozambique; Division of Clinical Microbiology, Department of Laboratory Medicine, Huddinge, Karolinska Institutet, Sweden; Universidade Eduardo Mondlane, Maputo, Mozambique
Tembe, Nelson (author)
Instituto Nacional de Saúde, Maputo, Mozambique; Division of Clinical Microbiology, Department of Laboratory Medicine, Huddinge, Karolinska Institutet, Sweden; Universidade Eduardo Mondlane, Maputo, Mozambique
Nilsson, Charlotta (author)
Karolinska Institutet
show more...
Meggi, Bindiya (author)
Instituto Nacional de Saúde, Maputo, Mozambique
Maueia, Cremildo (author)
Instituto Nacional de Saúde, Maputo, Mozambique
Augusto, Orvalho (author)
Universidade Eduardo Mondlane, Maputo, Mozambique
Stout, Richard (author)
Bioject Medical Technologies Inc, Tualatin OR, United States
Scarlatti, Gabriella (author)
Institute for Research and Health Care (IRCCS), San Raffaele Scientific Institute, Milan, Italy
Ferrari, Guido (author)
Department of Surgery and Molecular Genetics and Microbiology, Duke University Medical Center, Durham NC, United States
Earl, Patricia (author)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAD)/National Institutes of Health (NIH), Bethesda MD, United States
Wahren, Britta (author)
Karolinska Institutet
Andersson, Sören, 1957- (author)
Örebro universitet,Institutionen för medicinska vetenskaper,Department of Laboratory Medicine, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden
Robb, Merlin (author)
The Henry M. Jackson Foundation for the Advancement of Military Medicine, The Military HIV Research Program, Walter Reed Army Institute of Research, Bethesda MD, United States
Osman, Nafissa (author)
Universidade Eduardo Mondlane, Maputo, Mozambique
Biberfeld, Gunnel (author)
Karolinska Institutet
Jani, Ilesh (author)
Instituto Nacional de Saúde, Maputo, Mozambique
Sandström, Eric (author)
Microbiology,Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
show less...
 (creator_code:org_t)
Mary Ann Liebert, 2018
2018
English.
In: AIDS Research and Human Retroviruses. - : Mary Ann Liebert. - 0889-2229 .- 1931-8405. ; 34:2, s. 193-205
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • We assessed safety and immunogenicity of HIV-DNA priming using ZetajetTM, a needle-free device intradermally followed by intramuscular HIV-MVA boosts, in 24 healthy Mozambicans. Volunteers were randomized to receive three immunizations of 600 µg (n = 10; 2 x 0.1mL) or 1200 µg (n = 10; 2 x 0.2mL) of HIV-DNA (3 mg/mL), followed by two boosts of 108pfu HIV-MVA. Four subjects received placebo saline injections. Vaccines and injections were safe and well tolerated with no difference between the two priming groups. After three HIV-DNA immunizations, IFN-γ ELISpot responses to Gag were detected in 9/17 (53%) vaccinees, while none responded to Env. After the first HIV-MVA, the overall response rate to Gag and/or Env increased to 14/15 (93%); 14/15 (93%) to Gag and 13/15 (87%) to Env. There were no significant differences between the immunization groups in frequency of response to Gag and Env or magnitude of Gag responses. Env responses were significantly higher in the higher-dose group (median 420 vs 157.5 SFC/million PBMC, p=0.014). HIV-specific antibodies to subtype C gp140 and subtype B gp160 were elicited in all vaccinees after the second HIV-MVA, without differences in titers between the groups. Neutralizing antibody responses were not detected. Two (13%) of 16 vaccinees, one in each of the priming groups, exhibited antibodies mediating antibody-dependent cellular cytotoxicity to CRF01_AE. In conclusion, HIV-DNA vaccine delivered intradermally in volumes of 0.1-0.2 mL using ZetajetTM was safe and well tolerated. Priming with the 1200 µg dose of HIV-DNA generated higher magnitudes of ELISpot responses to Env.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Immunology in the medical area (hsv//eng)

Keyword

HIV
vaccine
Mozambique
HIV-DNA
HIV-MVA

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view